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Abstract

This paper explores dipeptidyl peptidase-4 (DPP-4) inhibitors as an additional treatment
option for patients with type II Diabetes Mellitus (DM) who are not controlled with
metformin. The purpose is to look at the research indicating the efficacy and benefits of
utilizing a DPP-4 inhibitor as an oral method for management of type II DM. Many patients
with type II DM are often resistant to use an injectable medication, like insulin as part of
their treatment plan. Many would like to continue to treat their diabetes with oral
medications and the use of DPP-4 inhibitors may make that possible. Current studies look
at the preservation of beta cell function and improved insulin sensitivity with the use of
DPP-4 inhibitors, as well as the ability to effectively manage type II DM without insulin
therapy (Utzschneider et al., 2017). By utilizing the DPP-4 inhibitors, the hope is to be able
to offer this patient population a safe and effective way to manage their diabetes while
prolonging the transition and possibly avoiding the need for insulin therapy.
Background
D. is a 60 year old Caucasian female who came to the clinic with a history of
hypertension, hyperlipidemia, and type II DM. She was diagnosed with type II DM
approximately 10 years prior. She has been managed on 500mg of Metformin twice daily.
She was unsure of what her previous Hemoglobin (Hgb) A1C had been in the past. In the
clinic, it was found that her DM was no longer controlled with a single oral medication and
an adjustment would have to be made in order to improve her long-term health. This
patient was willing to transition to insulin therapy if advised, which often times is not the
case for diabetic patients.
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There are other oral treatment options aside from metformin for individuals who
are unable to or are not ready to transition to insulin or other injectable therapy while
managing their diabetes. The option that will be addressed in this paper includes the use of
DPP-4 inhibitors. DDP-4 inhibitors have been found not only to control blood sugars, but
also to slow the decline of the beta cell function; which has been found to begin even prior
to ones diagnosis of DM (Croxtall & Keam, 2008). DPP-4 inhibitors have shown to not be as
effective as Metformin in terms of lowering Hgb A1C; however they have been found to be
very effective as a combination therapy (Croxtall & Keam, 2008). Metformin tends to work
in many different areas in the physiologic process of diabetes. These mechanisms include
decreasing hepatic glucose production and intestinal absorption as well as increasing the
peripheral glucose uptake and utilization (Woo & Robinson, 2016). Metformin is often
utilized as first line therapy because of the efficacy it has in lowering the Hgb A1C,
decreasing weight, and it’s positive effect on lipid levels (Woo & Robinson, 2016). If the
goal of the patient is to utilize oral agents for as long as possible and the patient is not
achieving their Hgb A1C goal with Metformin alone, the DPP-4 inhibitor drug class may be
an option.
Monotherapy with any oral medication is often unsuccessful in managing patient’s
long term with type II diabetes (Yoon et al., 2011). Yoon et al. (2011) state that the biggest
drawback to starting a patient on a single oral medication is that while titrating oral
dosages, patients are exposed to prolonged periods of hyperglycemia. This predisposes
them to an increased risk of vascular disease. Initiating a combination therapy at the time
of diagnosis will get a higher proportion of patients to goal versus the initiation of
monotherapy (Yoon et al., 2011). A better long term management of diabetes will help
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sustain the beta cell function in an individual, therefore increasing the efficacy of oral
treatments as well as decreasing the chronic effects of diabetes such as neuropathy,
retinopathy, and cardiovascular events.
Case Report
D. was in to the clinic on 3/10/2017 with the chief complaint of acute fatigue. She
had been in the diabetic educator’s office the week prior who suggested she be seen by
primary care. She was last seen by her primary care providers about six months ago and
states she is seen on a yearly basis. She has a history of hyperlipidemia, hypertension, and
type II DM. She reported it has been 10 years since she was first diagnosed with diabetes.
She has no neuropathy complaints; she gets annual eye exams and states that her primary
will do yearly foot exams. She does not personally examine her feet nor was taught to do
so. D.’s diabetes was managed with 500mg Metformin twice daily, her hypertension is
managed with Lisinopril 20mg daily, her hyperlipidemia is managed with 20mg
Atorvastatin daily and she also takes 81mg aspirin daily as well as a daily multivitamin.
She is allergic to Penicillin; the specific reaction was not noted. She reported never having
smoked or been around second hand smoke in the home. D. stated that she generally
checks her blood sugar twice a week and noticed that it had been running between 150200mg/dL. D. reported sleeping well, feeling refreshed in the morning and was not aware
of any snoring or apnea. D. also denied any recent weight gain or constipation.
D.’s physical exam revealed good blood pressure control at 120/80 and a pulse of 64
beats per minute. She was afebrile and reported no recent fevers or chills. Her neck was
supple; no masses were felt. She has a regular heart rhythm, no murmurs or rubs, and a
normal respiratory effort without any crackles or wheezes present upon auscultation. Her
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abdomen was soft, non-tender and bowel sounds present in all four quadrants. There was
no lymphadenopathy felt; she was alert and orientation x4, skin was warm, dry, no
abrasions, rashes, or lesions noted. She was noted to have full range of motion in all
extremities and she had a normal mood and affect. When doing her foot exam, she had
good sensation in all areas. She had no breakdown or callousing noted and good skin
condition between joints and phalanxes.
To assist in the management and diagnosis for the etiology of her fatigue, it was
decided to obtain some diagnostic lab work. A complete blood count was ordered to look
for anemia, a comprehensive metabolic count was ordered to assess electrolyte imbalances,
fasting blood glucose, and hydration status. A Hgb A1C was ordered to assess her overall
management of diabetes in approximately the past three months. Due to her
hyperlipidemia and the possible long terms effects due to her comorbidities; a fasting lipid
panel was drawn. This will help assess for the need for lifestyle or medication changes.
Lastly, a thyroid stimulating hormone was drawn to assess for thyroid function. If her
thyroid was not producing enough hormone; it could help to diagnosis a deficiency and
point to a possible source for her fatigue.
The only lab that was out of normal limits was her Hgb A1C at 8.3%. According to
Cefalu (2017), the goal is somewhere between 6.5% and 7% depending on the patient and
the practitioner. D.’s Hgb A1C indicated that her diabetes mellitus was in an uncontrolled
state. Since she was diagnosed with diabetes 10 years prior and has been on an oral
antihyperglycemic agent, lifestyle choices and changes were reinforced but were unable to
be the sole intervention. At this point in her care, it was important to discuss what she
would like to include in her pharmacological management. She was given the option of
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either pursuing another oral medication or starting a basal rate of insulin. Due to her 10
year history of diabetes, her age of 60 years and her fairly elevated Hgb A1C of 8.3%; a
basal insulin was encouraged, but the decision was ultimately left up to the patient. D. was
very receptive to starting a basal rate of insulin and decided that she was open to the
lifestyle changes associated with it.
D. was instructed to continue her same medication management, including the
metformin, but she now will add in a nightly insulin injection of Glargine. She will start
with a dose of five units nightly and increase it by one unit every two days if her blood
sugars continue to be above 150mg/dL. It was also asked that she check her blood sugar
twice daily, once in the morning and once in the evening and to keep a log of her results
with pertinent information. This included different snacks, meals, and/or exercise that
may have affected her glucose. She will plan to return to the clinic in 1 week for a reevaluation of her management and a possible adjustment of her insulin. A large portion of
this visit was centered around education in using the insulin pens, effects of insulin, signs
and symptoms of hypoglycemia as well as how to handle low blood sugars. She was given
an instruction sheet with a summary of the visit, a plan of care and how to take her insulin
and titrate it up to goal. All her questions were answered and she was given the clinic
phone number to call if any questions arise so that she can talk to the nurse or myself for
instructions. She was also advised to follow up with her primary care at least every three
months for now while managing her diabetes; if she would like to establish with myself for
management she was encouraged to do so. She was instructed on “red flag” symptoms and
to return to the clinic sooner with any acute changes or new concerns. Please refer to
Appendix A for the full progress note.
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Literature Review

Type II DM is a chronic disease that involves glycemic control, but also involves
managing comorbidities such as hypertension, obesity and dyslipidemia (Kasper et al.,
2014). Obtaining control of diabetes is very important to prevent damage to organs that
are necessary for living such as the kidneys. While some individuals are very receptive and
open to starting insulin like in D.’s case, others are not and an acceptable and effective
alternative treatment plan should be offered and utilized. It is important to consider the
individual’s own physiologic ability to either make insulin or be receptive to it.
When looking at the pharmacological management of this disease, it is important to
consider the physiological process that is taking place. DM type II involves a decreased
sensitivity to endogenous insulin as well as degradation of the beta cell function. This is
key in producing the insulin that is needed to drive the glucose into the body’s cells (Kasper
et al., 2014). Mu et al. (2006) observed that a class of medications, the DPP-4 inhibitors,
works as a key regulator in the incretin hormones. Incretins work in response to a meal by
stimulating insulin production and glucagon release, decreasing gastric emptying and
increasing satiety. These advantageous incretin hormones are ultimately destroyed by
dipeptidyl peptidase-4. By utilizing DPP-4 inhibitors, we are able to slow incretin
degradation, and ultimately increase mealtime insulin production, glucagon release, and
satiety. This will in turn decrease the overall blood glucose of an individual (Aschner et al.,
2006).
While it may not be traditionally done, DPP4-inhibitors have the possibility of being
utilized as a first line treatment in type II DM. Aschner, P. et al. (2006) looked at utilizing
the DPP-4 inhibitor class as a monotherapy. It was noted that a once daily dose of
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Sitagliptin (DPP-4 inhibitor) of at least 100mg inhibited plasma activity of the DPP-4
hormone by greater than 80%. That equates to an increase of two to three times more
active incretin hormone, increased insulin and decreased plasma glucose. By blocking the
hormones that lower insulin production and glucose release, there is an ability to decrease
the plasma glucose levels. This works primarily on post parandial glucose management,
which will help decrease an individual’s susceptibility to hypoglycemia episodes while on
this medication. Orally administered DPP4-inhibitors alone can decrease a hemoglobin
A1C by 0.5%-1.0% (Drucker & Nauck, 2006). For those who need more of a decrease to
obtain a goal Hgb A1C, one might need an additional therapy. While it is not yet supported
in literature to utilize the DPP-4 inhibitors as first line monotherapy; it might be a
medication that is utilized in the future for those who are unable to tolerate the use of
metformin for various reasons.
The most common agent to combine DPP4-inhibitors with is metformin. This is the
current standard of care (American Diabetes Association, 2017). Patients are commonly
started on metformin as monotherapy when they start to show signs and symptoms of type
II DM and their Hgb A1C is above 6.5%. As their Hgb A1C starts to rise, their dose of
Metformin will be increased as tolerated until their diabetes is controlled, or until they
reach a maximum dose of 2550 mg per day (Woo & Robinson, 2016). When additional
intervention is needed to control their hyperglycemia, supplementary treatment options
are looked at. Insulin therapy may not appeal to a diabetic patient, especially in the early
stages of treatment. It is now being found that earlier treatment can possibly prevent or
minimize the loss of beta cell function. (Mudaliar, S., 2013). Undoubtedly lifestyle changes
are the preferred way to prevent type II DM. While some people are able to treat or control
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their DM2 this way, for others additional treatment or intervention is needed. It is possible
that starting individuals on a dual therapy early in their treatment for diabetes is beneficial.
Yoon et al. (2011) state that an initial combination therapy may have a greater benefit on
the B-cell function and help an individual maintain a long-term glycemic control without
insulin. By utilizing two different antihyperglycemic agents, you will target different
physiological processes and therefore be more effective at lowering the plasma glucose
level. In utilizing a DPP-4 inhibitor you will increase the amount of active incretin
hormones in the body. The DDP-4 inhibitor drug class has been shown to have an apoptotic
and pro-proliferative effects on the B-cells. Another class of antihyperglycemics, the
thiazolidinediones, have an agonistic effect on receptors and have been shown to increase
B-cell structure and their ability to function as well as increasing the hepatic glucose output
and decreasing the insulin resistance. Through this method you might be able to utilize the
complimentary actions of oral agents and achieve a target Hgb A1C more effectively.
It is known that certain risk factors pre dispose some people to type II DM such as
physical inactivity, first degree relatives with type II diabetes, certain ethnic groups,
hypertension, hyperlipidemia, polycystic ovarian syndrome, and a history of cardiovascular
disease (American Diabetes Association, 2017). There also are screening guidelines as
well, which is secondary prevention. The American Diabetes Association (2017)
recommends that fasting blood glucose screening should begin at age 45 and if results are
normal, testing should be repeated every three years. What experts are not as concrete on
is what occurs physically during the prodromal period of development of diabetes. How
early or how late before diagnosis does the beta cell function start to decline? Would
treatment with a DPP4-inhibitor before diagnosis (those with a high enough risk) benefit?
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If this process can be identified, medication therapy can potentially be utilized to prevent
or prolong the development of type II DM with early recognition. An article by Tabak et al.
(2009) attempted to look at the pathological process and timing of impaired glucose
tolerance, insulin sensitivity, and insulin secretion in type II diabetes. These individuals
found that beta cell function has an abrupt and short-lived elevation between years three
and four prior to the diagnosis of type II DM. After that small spike in productivity, the
function of the beta cells begins to decrease and hyperglycemia becomes evident. This will
continue until a diagnosis of type II DM is made. Knowing this trend, it is possible that in
the future this will be a target for therapy in the prevention or prolongation of type II
diabetes.
Important to include in consideration for treatment in an individual with type II
diabetes is the degree of exhaustion in the beta cells. While our case study, D., was
diagnosed with diabetes 10 years prior, her beta cell function most likely started the
decline about 13 years ago. She made the choice to begin injection therapy with insulin,
which was encouraged by her practitioner. While the DPP-4 inhibitor is another option
and one that is worth a try, you may not see as good of results as with insulin due to the
possible exhaustion of her beta cells.
Some of the attractions to using a DPP-4 inhibitor in patients are that they
essentially work to augment a natural hormone or process that already exists. Many times
synthetic products are created that are suitable for pharmacological therapy. The downside
is that they may have multiple side effects or interactions. The DPP4-inhibitors tend to not
have many side effects due to this natural augmentation. There can be some
gastrointestinal side effects such as nausea and vomiting, but these side effects do tend to
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recede after therapy has been stabilized. The most important thing to remember is to start
low and go slow with titration (Svec, 2010). Another side effect that should be recognized
is unexplained joint aches and pains. These can occur at the start of treatment or
unprecedented a year later. According to Lowes (2015), this pain will recede within a
month of cessation of the medication. With a DPP4-inhibitor, the degradation of DPP-4 is
prevented. It is theorized that through this mechanism, another enzyme that degrades
something in the inflammatory process is inhibited, therefore leading to these aches and
pains. Zhong et al. (2015) reported that the DPP-4 enzyme may affect cardiovascular
function through the regulation of inflammation. The authors state that the DPP-4 enzyme
is highly present on many of the inflammatory cells, such as the T cells, and that it generally
will control their function. In some individuals, inhibition of this enzyme may cross over to
their joints and cause pain as a side effect. While D. does not have any rheumatologic
concerns or chronic pain, individuals that do have these comorbidities may not be
appropriate candidates for this choice of therapy.
Diabetes has multiple complications, one of them being cardiovascular disease.
Because of this, Nga et al. (2011) researched the effects that DPP4-inhibitors have on the
cardiovascular system. It was found that DPP-4 inhibitors reduced the amount of
atherosclerotic lesions that were present in diabetic mice. The importance of this finding is
that while utilizing DPP4-inhbitors to manage diabetes, atherosclerotic lesions are being
reduced, and therefore the amount of diabetic complications is decreased.
When examining the effect that DPP-4 inhibitors have on the development of
atherosclerotic plaques, it does make sense that individuals who have higher levels of
incretin hormones in the body tend to have lower levels of cardiovascular disease.
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Matsbubara et al. (2012) state that DPP-4 inhibitors work to phosphorylate the nitric oxide
produced by the epithelium and therefore reduce the amount of atherosclerosis that
accumulates over time and in diseased states. This process is one of the main components
in diabetic complications, and many individuals tend to face multiple comorbidities that
put them at high risk. In the case study of D., it would be ideal to utilize a DPP-4 inhibitor to
not only manage her hyperglycemia but also to combat her comorbidities of hypertension
and hyperlipidemia. Reducing atherosclerotic plaques in her vasculature system will help
to reduce the progression of her comorbidities as well as prevent the development of other
complications such as small vessel disease in the form of neuropathy, nephropathy, or
retinopathy.
Learning Points
•

DPP4-inhibitors are starting to be studied as a monotherapy agent in the control of
diabetes. They have not been found to be more effective than metformin, however they
may be an alternative if metformin is not an option.

•

Dual therapy with two oral agents earlier in treatment may better effectively manage
diabetes and prolong the time until insulin is needed.

•

While beta cell function has been found to decline about three years prior to diagnosis
of diabetes, DPP4-inhibitors have been found to increase the function of the beta cells
as well as reduce the amount of apoptosis that occurs.

•

An attraction to DPP-4 inhibitors over other pharmacological interventions is that they
augment a natural process instead of utilizing a synthetic product. They are also weight
neutral, they have a low propensity for hypoglycemia, and they have a low interaction
rate with other medications.
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DPP-4 inhibitors affect on the cardiovascular system by reducing the amount of
atherosclerosis present. They work to phosphorylate the nitric oxide and stabilize the
epithelium that is preset in the vasculature. This should decrease and prolong the
diabetic associated comorbidities such as hypertension and hyperlipidemia.
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Appendix A

Progress Note for D.
CC
D. is a 60yr of female who presents today for diabetes recheck. She saw her diabetes
educator last week and was encouraged to follow up in the clinic.
HPI
D. is a new patient who presents today for a follow up on diabetic care. She saw her
diabetic educator approximately 1 week ago who encouraged her to schedule a follow up in
the clinic. She reports that her last follow up with her primary was about 6 months ago and
that she is seen in the clinic on a yearly basis for management. She states that she has been
a diabetic for about 10 years and has been “well managed” during that time period. She
states she does get annual eye exams and her most recent was in May 2016. She does not
routinely examine her feet but states that her primary does this during her yearly visits.
She does report checking her sugars about twice a week and they are currently running
anywhere between 150-200mg/dL. She does not check them at a consistent time during
the day. She is not a smoker, she is not exposed to second hand smoke, nor has she ever
smoked in the past. Currently her only symptom that she has noticed recently, is she is
more fatigued. She reports sleeping well, feeling refreshed in the morning, and does not
report any observed snoring or apnea. She is unaware if she has ever had her thyroid
checked; however she denies any recent weight gain, or constipation.
Medications
Metformin 500mg twice daily
Aspirin 81mg daily
Lisinopril 20mg daily
Atorvastatin 20mg daily
Multivitamin daily
Allergies
Penicillin
PMH/Problem List
Dyslipidemia, Hypertension, Diabetes Mellitus type 2
Social History
D. lives independently in a private home with a significant other. She continues to have a
job where she works 40 hours a week. She does have living children.
ROS
See HPI
Physical Exam
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BP 120/80 Pulse 64 Temp 98.3 SpO2 90% on Room Air
Constitutional: Patient is well groomed, in no acute distress, does not appear ill.
HENT: Head normocephalic, atraumatic, nasal mucosa pink, no septal deviation, no
rhinorrhea, oropharynx clear and moist, posterior pharynx without edema or exudate
Eyes: PERRLA, conjunctivae without injection, no discharge
Neck: supple, no masses, trachea midline
Cardiovascular: Regular rhythm, S1 and S2 normal. Exam reveals no S3 or S4. No murmur,
rubs, or gallop. Brisk capillary refill. No peripheral edema.
Pulmonary/Chest: Effort normal, symmetric unlabored respirations, no respiratory
distress, no crackles or wheeze, no chest tenderness
GI: soft, non-tender to palpation, bowel sounds present x4, no splenomegaly
Lymphadenopathy: No retropharyngeal, submental, submandibular, preauricular, post
auricular, cervical, occipital, or supraclavicular lymphadenopathy appreciated.
Neurological: Alert and oriented x 3
Skin: Warm and dry, no abnormal lesions or rashes
Musculoskeletal: full range of motion without pain
Psychiatric: Normal mood and affect.
Differential Diagnoses
Hypothyroidism
Sleep Apnea
Uncontrolled Diabetes Mellitus type 2
Lab data/Diagnostics
CMP unremarkable
CBC unremarkable
Fasting Lipid Panel unremarkable
TSH unremarkable
Hgb A1C = 8.3
Course/Plan
Diagnostics ordered as above
A discussion was had with D. concerning her lab data and diagnostics. Her tests were
unremarkable aside from an elevated Hgb A1C at 8.3. Her current medication regimen of
Metformin 500mg BID is no longer controlling her diabetes mellitus type 2. She was
educated on current lifestyle changes and management with inclusion of exercise and diet
modification. It was discussed whether she would like to increase or add on another oral
medication; or if she would like to start daily dosing of a basal rate insulin. Due to her 10year history of diabetes mellitus, age of 60 years and possible declining beta cell function,
basal rate insulin was recommended as first line therapy. D. was very agreeable to starting
a basal rate of insulin at this time. She was instructed to continue her metformin at 500mg
BID and to start nightly Glargine at 5units. She is going to check her sugars twice daily in
the morning and then at night, and keep a log along with pertinent foods and comments
that surround either high or low blood sugars. She is going to increase her Glargine by 1
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unit every 2 days if her blood sugars remain above 150mg/dL. She was educated on the
signs and symptoms of hypoglycemia and how to manage at home. I will plan to see her
back in the clinic in 1 week for an evaluation of her management and a recheck of a fasting
blood sugar. It was discussed that she should be seen by a primary more often and a Hgb
A1C monitoring at least every 3 months until we are at a more stable control, if she does
not have an appointed primary she is welcome to establish with myself. She was advised to
return to the clinic sooner if she has any increasing symptoms or acute changes. D.
verbalized an understanding and was agreeable to the plan of care.

